Increased vascular resistance and not salt retention characterizes cyclosporine A-induced hypertension: Report in an anuric patient

American Journal of Transplantation

Volumn 7, Issue 8, 2007, Pages 2042-2046

  Wahba, I M ^a   Bennett, W M ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^c Novartis Oncology ^*  (Switzerland)

Author keywords

Bioimpedance; Calcineurin inhibitor; Cyclosporin; Hypertension; Sodium retention; Vascular resistance

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLONIDINE; CYANOCOBALAMIN; CYCLOSPORIN A; ERYTHROPOIETIN; IMMUNOGLOBULIN; LISINOPRIL; NIFEDIPINE; SEVELAMER; THYMOCYTE ANTIBODY; VITAMIN;

ADD ON THERAPY; AGED; ANURIA; APLASTIC ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FAILURE; MUSCLE CRAMP; PRIORITY JOURNAL; SODIUM RETENTION; STOMACH DISCOMFORT; VASCULAR RESISTANCE; VITAMIN SUPPLEMENTATION;

AGED; ANURIA; BLOOD PRESSURE; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; SODIUM CHLORIDE; VASCULAR RESISTANCE;

EID: 34447114478     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01871.x     Document Type: Article

References (25)

1. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: Incidence, pathogenesis and management. Drug Saf 1999 20 : 437 449.
2. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988 85 : 134 138.
3. Hartmann A, Schwietzer G, Stratmann D, Kaltenbach M, Kober G. Effects of nitrendipine and lisinopril on blood pressure and sodium excretion in ciclosporin-associated hypertension after heart transplantation. Cardiology 1993 83 : 141 149.
4. Seals DR, Victor RG, Mark AL. Plasma norepinephrine and muscle sympathetic discharge during rhythmic exercise in humans. J Appl Physiol 1988 65 : 940 944.
5. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987 44 : 135 141.
6. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A 1985 82 : 8222 8226.
7. Epting T, Hartmann K, Sandqvist A, Nitschke R, Gordjani N. Cyclosporin A stimulates apical Na+/H+ exchange in LLC-PK1/PKE20 proximal tubular cells. Pediatr Nephrol 2006 21 : 939 946.
8. Sturrock ND, Lang CC, MacFarlane LJ et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995 13 : 667 673.
9. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987 83 : 59 64.
10. Van Der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995 25 : 77 81.
11. Morgan BJ, Lyson T, Scherrer U, Victor RG. Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991 18 : 458 466.
12. Zhang W, Li JL, Hosaka M et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A 2000 97 : 9765 9770.
13. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993 88 : 1101 1109.
14. Stein CM, He H, Pincus T, Wood AJ. Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 1995 26 : 705 710.
15. Elzinga LW, Rosen S, Burdmann EA, Hatton DC, Lindsley J, Bennett WM. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000 69 : 2149 2153.
16. Hausberg M, Lang D, Levers A et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006 24 : 957 964.
17. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999 340 : 1321 1328.
18. Rego A, Vargas R, Suarez KR, Foegh ML, Ramwell PW. Mechanism of cyclosporine potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: Role of extracellular calcium. J Pharmacol Exp Ther 1990 254 : 799 808.
19. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett W. Vascular mechanisms of cyclosporine-induced hypertension in the rat. J Clin Invest 1994 93 : 2244 2250.
20. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993 91 : 2144 2149.
21. Richards NT, Poston L, Hilton PJ. Cyclosporin A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels. J Hypertens 1990 8 : 159 163.
22. Gaston RS, Schlessinger SD, Sanders PW, Barker CV, Curtis JJ, Warnock DG. Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients. J Am Soc Nephrol 1995 5 : 1426 1433.
23. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension 2002 39 : 982 988.
24. Textor SC, Schwartz L, Wilson DJ et al. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 1994 23 (1 Suppl I220 224.
25. Taler SJ, Textor SC, Canzanello VJ et al. Hypertension after liver transplantation: A predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations. Am J Hypertens 2000 13 : 231 239.